

UNIVERSITI TEKNOLOGI MARA

**INVESTIGATION OF THE
PATHWAYS INVOLVED IN THE
ACQUIRED RADIORESISTANT
EMT6 MOUSE MAMMARY
CARCINOMA CELLS TO GAMMA-
RAY IRRADIATION: *IN VITRO* AND
IN VIVO STUDIES**

**NUR FATIHAH BINTI RONNY
SHAM**

Thesis submitted in fulfilment
of the requirements for the degree of
Doctor of Philosophy
(Medicine)

Faculty of Medicine

January 2024

ABSTRACT

Resistance of breast cancer to radiotherapy is the crucial aspect leading to relapse and low survival rate. Radioresistance is suggested to be linked with epithelial-mesenchymal transition (EMT), a process involved in regulating cancer tissue remodelling, resulting in recurrence and metastasis. The underlying mechanisms in acquiring radioresistance to gamma-ray in mouse mammary cancer cell lines (EMT6) were investigated using both *in vitro* and *in vivo* approaches. EMT6 cells were irradiated with gamma-ray at 2 Gy/cycle to initiate the development of radioresistance *in vitro*. Confirmation of EMT6 cells acquired radioresistance was analysed using migration and clonogenic assays. Next-generation sequencing analysis validated 16 genes of interest (GOI) via real-time polymerase chain reaction (qPCR). The signalling pathways and proteins involved in EMT6 cells acquiring radioresistance were verified by KEGG pathway analysis and western blotting, respectively. EMT6^{RR_MJI} radioresistance cells were developed from parental EMT6 cells after 8 cycles of fractionated gamma-ray irradiation. This is confirmed by irradiation with gamma-ray at 2, 4, and 8 Gy, which resulted in higher survival fractions and migratory rates of EMT6^{RR_MJI} compared to parental cells. Six out of 16 GOIs (PD-L1, IL-6, AXL, GAS6, IGFBP4, and APCDD1) were upregulated at the 8th irradiation cycle in EMT6^{RR_MJI} compared to control. Pathway analysis showed PI3K-AKT and JAK-STAT signalling pathways were the common functional pathways contributing to radioresistance by these six genes. Further investigations focused on PD-1 gene and protein expressions, in which PD-1 is the crucial regulator of PI3K-AKT and JAK-STAT pathways. PD-1 gene and protein expressions were upregulated in EMT6^{RR_MJI} compared to parental cells ($p < 0.05$, $p < 0.05$, respectively). The role of PD-1 in radioresistance was further investigated *in vivo*. Mice were divided into 3 groups: Group 1 (control), Group 2 (inoculated with parental EMT6 cells), and Group 3 (inoculated with EMT6^{RR_MJI} cells). Groups 2 and 3 were further subdivided into 4 subgroups: Subgroup 1 (control, $n=6$), Subgroup 2 (gamma-ray irradiation, $n=6$), Subgroup 3 (combination of gamma-ray and Nivolumab, a PD-1 inhibitor, $n=6$) and Subgroup 4 (Nivolumab, $n=6$). Mice in subgroups 3 and 4 were further injected with 10 mg/kg body weight Nivolumab at 3 time points. Once the tumour was palpable and visible in all groups, the mice in subgroups 2 and 3 were treated with gamma-ray at 2 Gy per cycle for 8 cycles. Tumour volumes were measured every 2 days. The mice in all groups were sacrificed 5 days post-irradiation and tumour sections were collected to determine the expression of N-cadherin, E-cadherin, PD-1, and PD-L1 using qPCR, while the PD-1 protein was analyzed by western blot and ELISA. N-cadherin and E-cadherin were upregulated and downregulated, respectively, in both tumours. The tumours were confirmed to be derived from proliferative EMT cells. In the parental EMT6, tumour growth in subgroups 2 ($p < 0.01$), 3 ($p < 0.001$), and 4 ($p < 0.01$) decreased compared to control. Furthermore, PD-1 gene expression was higher in subgroup 2 ($p < 0.05$) compared to the control group. PD-1 protein expression increased in subgroup 4 ($p < 0.05$) but reduced in subgroup 2 ($p < 0.05$) as compared to control. For the EMT6^{RR_MJI} tumour, the growth in subgroup 3 was lower in control ($p < 0.001$) group. PD-L1 gene expression decreased in subgroups 2 and 4 compared to EMT6^{RR_MJI} control ($p < 0.05$). PD-1 protein expression was reduced in subgroups 2 and 3 compared to the control group ($p < 0.05$). In conclusion, EMT6^{RR_MJI} acquired resistance to gamma-ray is associated with the upregulation of PD-1/PD-L1 signalling. However, no conclusive evidence suggests Nivolumab inhibits PD-1 expression. Extending the duration of post-treatment is required to elucidate these possible mechanisms, which may provide knowledge for the potential adjuvant treatment during radiotherapy in reducing resistance and recurrence.

ACKNOWLEDGEMENT

In the name of Allah, the most Gracious and the most Merciful.

I would like to express my deepest gratitude to everyone who has played a significant role in my journey to earning my PhD. Firstly, I am immensely thankful to my supervisor Associate Professor Dr Mohammad Johari Ibahim. Your unwavering belief in my abilities and your dedication to my academic growth have been instrumental shaping my research and guiding me through the challenges of this doctoral journey. I extend my gratitude to my co-supervisor Associate Prof. Dr. Narimah Abdul Hamid Hasani, who always supported me. Your kind and encouraging words have been like a warm embrace during this challenging time. My gratitude also for _____ and _____ for their knowledge and expertise throughout this journey. I am indebted to my seniors, _____ and _____ for their generosity in sharing their knowledge and experience with me and also to always told me to not give up. Special thanks given to _____ from the Department of Pharmacology who also guided me throughout my journey. To my friends and peers – _____ thank you for being the constant source of laughter and happiness throughout the journey. Your humor is truly appreciated. To _____ thank you for being a source of motivation during the challenging moments of this journey. Your support made this endeavour more enjoyable and meaningful.

And of course – my Baiyohenol and Bio B team – _____ thank you for being there from day one. Thank you for all the memories, for all the ‘crime’ we did together (haha), as we laughed until tears flowed during those magical Avalon nights. Those moments will forever be etched in my heart. Special thanks to _____ for being an incredible source of support, laughter and your encouragement during both the highs and lows.

I am indebted to the staff and Faculty of Medicine, UiTM Sungai Buloh Campus, Institute of Medical Molecular Biotechnology (IMMB) and Laboratory Animal Care Unit (LACU), who provided a nurturing academic environment, access to resources, and opportunities for intellectual growth. My special thanks also to _____ from the Faculty of Science Nuclear, Universiti Kebangsaan Malaysia, and the Gamma-ray laboratory Universiti Kebangsaan Malaysia. Most importantly, the grants received from both UiTM and the Ministry of Higher Education, Malaysia, support research expenses.

To my father _____ my siblings – _____ and one and only _____ my cheeky boy, thank you for unwavering support, love and understanding. We should plan a vacation very soon!

Lastly, I would like to dedicate this achievement to my mother _____ Your belief in me even when I doubted myself, was a constant source of motivation. Your sacrifices and understanding when I had to prioritize my studies meant the world to me. I want you to know that this achievement is as much yours as it is mine. Without your love and support, I wouldn’t have made it this far. Thank you, Umi. I love you more than words can express, and I am forever grateful for everything you’ve done for me.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF ABBREVIATIONS	xix
CHAPTER 1 INTRODUCTION	1
1.1 Background of study	1
1.2 Significance of Study	3
1.3 Problem Statement	3
1.4 Research Questions	4
1.5 Research Hypotheses	5
1.6 Research Objectives	5
1.6.1 Specific Objectives	5
1.6.2 Scope and Limitations of Study	6
CHAPTER 2 LITERATURE REVIEW	7
2.1 Introduction to Cancer	7
2.1.1 Epidemiology of Cancer	7
2.1.2 Cancer Biology	12
2.2 Breast Cancer	13
2.2.1 Overview of breast cancer	13
2.2.2 Tumour, Node, Metastasis (TNM) Staging	14
2.2.3 Molecular subtypes of breast cancer	16
2.3 Breast cancer signalling pathways	19
2.3.1 RAS signalling pathway	19

CHAPTER 1

INTRODUCTION

1.1 Background of study

Cancer is a condition in which abnormal cells proliferate out of control and metastasis to other locations. Cancer is the second leading cause of death after cardiovascular disease (Ritchie et al., 2018). Out of 19.3 million new cases diagnosed in 2020, lung (2.21 million) and breast (2.26 million) are the most common types of cancer among men and women, respectively (Sung et al., 2021). Despite extensive research conducted, its aetiology remains poorly understood with the contributing factors not fully discovered.

Breast cancer is the leading cause of death among women in Malaysia and globally (*Cancer Today*, 2020.; Sung et al., 2021). It is characterised by the multiplication of progressive cells leading to the uncontrollable development of tissue masses or tumours in the breast (*Breast Cancer Overview*, 2020.). Benign breast tumours are non-invasive or occasionally precancerous, while malignant tumours can invade and colonise secondary sites (*What Is Cancer?*, 2007). Some malignant tumours developed invasive characteristics enabling them to metastasis from the original site, and migrate through various transporting channels, such as the blood circulation and/or lymphatic system, to initiate secondary site colonisation (Christofori, 2006; Hapach et al., 2019). The metastasis mechanisms involved complicated cell division pathways from the main tumours, invasion, immune monitoring, and control of the tissue microenvironment. Interestingly, epithelial-mesenchymal transition (EMT) is required for metastasis in most malignancies (Williams et al., 2019)

The link between the initiation of breast cancer metastasis and EMT, a condition in which epithelial cell polarity and intercellular cohesiveness are disrupted has been documented (Brabletz et al., 2018). Cell-cell adhesion and cellular polarity are disrupted throughout the EMT process, and modifications in cell-matrix adhesion. EMT is induced in malignancies by hypoxia, cytokines, and growth factors secreted by the tumour's microenvironment, stromal crosstalk, metabolic changes, innate and adaptive immune responses, and anticancer pharmaceutical therapy (Roche, 2018). Interleukin-